Andrew Callos, who serves as Executive Vice President and Chief Commercial Officer at Cytokinetics INC (NASDAQ: CYTK), completed a sale of 3,639 shares of the companys common stock on March 31, 2026. The shares changed hands at $65.00 apiece, for a total transaction value of $236,535.
The disposal occurred while Cytokinetics shares traded near their 52-week high of $70.98 and following a 57% gain over the previous 12 months. After the sale, Callos retains direct ownership of 66,004 shares in the company.
Market analysis from InvestingPro indicates that Cytokinetics is trading near its Fair Value and notes an $8.11 billion market capitalization for the company. According to the same analysis platform, there are 11 additional ProTips available to subscribers who are evaluating the stock.
Alongside this insider transaction, several sell-side research teams have updated their views and price targets for Cytokinetics:
- Mizuho increased its price target to $100, citing an extension of the aficamten intellectual property projection and a higher probability of success for the non-obstructive hypertrophic cardiomyopathy program.
- JPMorgan raised its price target to $75, maintained an Overweight rating, and pointed to optimism following approval of Myqorzo for obstructive hypertrophic cardiomyopathy.
- Stifel reiterated a Buy rating with a $98 price target and highlighted a 70% probability of success for the upcoming ACACIA trial.
- Leerink Partners kept an Outperform rating with an $84 price target, expressing confidence in the U.S. launch of Myqorzo and the anticipated ACACIA-HCM Phase 3 readout.
- UBS lifted its price target to $69, noting increased confidence in the non-obstructive hypertrophic cardiomyopathy program.
These analyst moves show varying degrees of optimism across the broker community about Cytokinetics clinical programs and commercial prospects. The recent insider sale and the cluster of research updates were contemporaneous, but the reporting here reflects only the transaction and the public analyst commentary.
Context and positioning
The sale by Callos reduces his direct holding but leaves him with a substantial equity stake. The company's stock performance over the past year and the multiple analyst price-target changes are central inputs for investors assessing valuation and program risk. InvestingPros assessment that the shares are trading near Fair Value is noted alongside the platforms subscriber tools.